Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Breast 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1HER2-positive Metastatic Breast Cancer 1HER2-low Breast Cancer 1

Interventions

pembrolizumab 28Trastuzumab 16Paclitaxel 14Docetaxel 12Cyclophosphamide 11Capecitabine 11Nivolumab 9fludarabine 7Carboplatin 7Oxaliplatin 6Magnetic Resonance Spectroscopy 6Cisplatin 6Specimen Handling 5Leucovorin 5Irinotecan 5Injections 5Gemcitabine 5Fluorouracil 5Bevacizumab 5atezolizumab 4aldesleukin 4Taxes 4Ipilimumab 4Fluorodeoxyglucose F18 4Drug Therapy 4Cetuximab 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4zanidatamab 3veliparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × RC48 antibody × Breast × Clear all
NCT06157892 2026-05-05

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Seagen Inc.

Phase 2 Recruiting
172 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡